Literature DB >> 29764220

Wide-range CRP versus high-sensitivity CRP on Roche analyzers: focus on low-grade inflammation ranges and high-sensitivity cardiac troponin T levels.

Denis Monneret1, Fouzi Mestari1, Shaedah Djiavoudine1, Guillaume Bachelot1, Maxime Cloison1, Françoise Imbert-Bismut1, Maguy Bernard1,2, Pierre Hausfater3,4, Jean-Marc Lacorte2,5, Dominique Bonnefont-Rousselot1,6.   

Abstract

Wide-range C-reactive protein (wr-CRP) has been proposed as an economical alternative to high-sensitivity C-reactive protein (hs-CRP) for the evaluation of low-grade inflammation-associated cardiovascular risk (LGI-CVR). Concomitant values of serum hs-CRP and plasma wr-CRP ≤5 mg/L, and high-sensitivity cardiac troponin T (hs-cTnT), all assayed on Roche Diagnostics analyzers over a 1.8-year period, were extracted from a hospital laboratory database. Hs-CRP and wr-CRP values were compared (Bland-Altman method; Deming's correlation), then separately classified into low (<1 mg/L), moderate (1-3 mg/L) and high (>3 mg/L) LGI-CVR ranges for agreement test (κ), assessed before and after Deming's regression-based adjustment of wr-CRP (Adj-wr-CRP). Wr-CRP and hs-CRP values were strongly correlated, with linearity, whether below 5 mg/L (n = 744; τ = 0.933; p < .001) or below 1 mg/L (n = 283; τ = 0.823; p < .001). Overall, wr-CRP values were lower than hs-CRP (mean bias: -0.11 ± 0.17 mg/L). Agreement was good, with 8.1% of wr-CRP values misclassified compared to hs-CRP (κ: 0.874), and weakly improved after regression-based adjustment (7.7% reclassified values; κ: 0.881). Lowering the Adj-wr-CRP cutoff of the moderate LGI-CVR subrange from 1.0 to 0.9 mg/L resulted in an almost perfect agreement (3.2% reclassified data; κ: 0.950). Hs-cTnT concentration was positively associated with hs-CRP, wr-CRP, and Adj-wr-CRP (p < .001). Within each LGI-CVR subrange, hs-cTnT medians were similar regardless of the hs-CRP, wr-CRP or Adj-wr-CRP used for risk classification. Based on hs-cTnT, this study supports the use of wr-CRP as a low-cost alternative to hs-CRP for cardiovascular risk evaluation.

Entities:  

Keywords:  C-reactive protein; cardiovascular risk; cardiovascular system; inflammation; troponin T

Mesh:

Substances:

Year:  2018        PMID: 29764220     DOI: 10.1080/00365513.2018.1471618

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

1.  Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

Authors:  Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2020-01-24       Impact factor: 8.860

Review 2.  Diagnoses Based on C-Reactive Protein Point-of-Care Tests.

Authors:  Miroslav Pohanka
Journal:  Biosensors (Basel)       Date:  2022-05-17

3.  Clinical significance of Glasgow Prognostic Score in patients with tuberculous pleurisy.

Authors:  Hye Seon Kang; Hwa Young Lee; Jung Im Jung; Ju Sang Kim; Yong Hyun Kim; Seung Joon Kim; Seok Chan Kim; Soon Seog Kwon; Young Kyoon Kim; Ji Young Kang
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

4.  A comparison study between wide-range and high-sensitivity C-reactive protein assays (Roche Cobas c702) for low C-reactive protein concentration in patients with cardiovascular risk.

Authors:  Runqing Li; Yajun Xue; Tengjiao Wang; Lijun Gong; Peng Peng; Pan Xiong; Mingzhu Dai; Tongju Shao; Yuhan Hu; Xinchen Ye
Journal:  J Clin Lab Anal       Date:  2019-06-20       Impact factor: 2.352

5.  Obesity, dyslipidemia, and high blood pressure are associated with cardiovascular risk, determined using high-sensitivity C-reactive protein concentration, in young adults.

Authors:  Luz Elena Ramos-Arellano; Ines Matia-Garcia; Linda Anahi Marino-Ortega; Natividad Castro-Alarcón; José Francisco Muñoz-Valle; Lorenzo Salgado-Goytia; Aralia Berenice Salgado-Bernabé; Isela Parra-Rojas
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.